Composite neoantigen presentation score is more strongly associated with response to therapy than neoantigen burden alone. A, Composite NEOPS is significantly higher in responding patients compared with nonresponding patients (n = 48; MWW; P = 0.002). B, Similar findings were observed in the validation cohort, with high responding patients presenting significantly higher NEOPS (n = 110; MWW; P = 0.010). C, Significantly longer PFS was observed in patients with high NEOPS when compared with those with low NEOPS (two-sided KM log-rank test; P = 0.0046). Boxplots in A and B cover the IQR from the 25th percentile at its lower bound to the 75th percentile at its upper bound, with median indicated by a horizontal line. The upper whisker includes the largest value within 1.5× IQR above the 75th percentile. The lower whisker includes the smallest value within 1.5× IQR below the 25th percentile. D, AUROC for the NEOPS model was 0.76, and the cross-validation AUROC mean was 0.75 (log-likelihood ratio P = 0.0057).